Clinical Outcomes of Third-Generation Cephalosporins, Carbapenems, and Piperacillin-Tazobactam in the Treatment of AmpC- Associated Enterobacterales Species Sepsis

作者
Mohammad Gharbeyah,Razan Rabi,Ahmad Al Bishawi,Mamon W. Swaileh,Gana Odeh,Jalal Abuomar,Ali Sabateen
出处
期刊:Research Square
标识
DOI:10.21203/rs.3.rs-7651779/v1
摘要

Abstract Background AmpC-producing Enterobacterales are associated with resistance to many β-lactam antibiotics, and the optimal treatment approach remains challenging. The primary aim is to describe real-world outcomes of hospitalised patients with AmpC-associated Enterobacterales infections treated with different antibiotics. Methods This was a retrospective cohort study, including hospitalised patients with confirmed infections based on clinical evaluation and laboratory confirmation caused by AmpC-producing Enterobacterales. Patients received definitive therapy using 3GCss, piperacillin-tazobactam, or carbapenems, based on final culture results showing full susceptibility to the administered antibiotics. Results Patients were categorised into 3GCs, piperacillin-tazobactam, and carbapenem treatment groups. Significant baseline differences were observed; the carbapenem group included patients with higher rates of shock (32.4%) and mechanical ventilation (26.5%), compared to lower rates in the 3GCs group (shock 7%, mechanical ventilation 17%). After adjustment for potential confounders, Clinical failure rates were 17% for the 3GCs group, 32% for the piperacillin-tazobactam group, and 41% for the carbapenem group. The 28-day mortality (7%) and overall mortality (12%) were lowest in the 3GC group, followed by the piperacillin-tazobactam group (14.7% 28-day mortality). Conclusion In this real-world cohort, mortality and clinical failure appeared lower among patients with AmpC-associated Enterobacterales infections who received third-generation cephalosporins or piperacillin-tazobactam compared with carbapenems. These findings suggest that third-generation cephalosporins and piperacillin-tazobactam might be reasonable options in selected, less critically ill patients, but larger prospective studies are needed to better define their role, as these results are exploratory.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yanxi完成签到,获得积分10
1秒前
sky发布了新的文献求助10
1秒前
FFF团团长发布了新的文献求助10
1秒前
Hhong完成签到,获得积分10
2秒前
娜娜完成签到,获得积分0
2秒前
蓝梦之旅完成签到,获得积分10
2秒前
3秒前
yangching完成签到,获得积分10
3秒前
儒雅的石头完成签到,获得积分10
3秒前
顾矜的应助被369ninja采纳,获得10
3秒前
liangzai完成签到,获得积分10
3秒前
4秒前
阳明爸爸完成签到,获得积分10
4秒前
wwwteng呀发布了新的文献求助10
4秒前
xxx完成签到,获得积分10
4秒前
Nicholas完成签到,获得积分10
5秒前
大猫完成签到,获得积分10
5秒前
kooolooo完成签到 ,获得积分10
5秒前
5秒前
彳亍而上学完成签到,获得积分10
6秒前
熊大完成签到,获得积分10
6秒前
含着朵白云完成签到 ,获得积分10
7秒前
我真的晕完成签到,获得积分10
7秒前
慈祥的爆米花完成签到,获得积分10
7秒前
LG完成签到 ,获得积分10
7秒前
FashionBoy的应助被科研通管家采纳,获得10
8秒前
elang发布了新的文献求助10
8秒前
syvshc的应助被科研通管家采纳,获得10
8秒前
斯文败类的应助被科研通管家采纳,获得10
8秒前
SciGPT的应助被科研通管家采纳,获得10
8秒前
Daniel完成签到,获得积分10
8秒前
思源的应助被科研通管家采纳,获得10
8秒前
suzhenyue的应助被科研通管家采纳,获得10
8秒前
单薄涵梅完成签到,获得积分10
8秒前
小二_来篇一作完成签到,获得积分10
8秒前
8秒前
Jin完成签到,获得积分10
9秒前
Akim的应助被科研通管家采纳,获得10
9秒前
Firsterchao的应助被科研通管家采纳,获得10
9秒前
Lin完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039